Diligence memo · auto-generated · as of July 2, 2026
Inhibrx, Inc.
Inhibrx, Inc. has raised $669M over 5 rounds; too few niche peers to rank its valuation yet.
Businessfiled
Inhibrx, Inc. operates in Biotechnology, based in LA JOLLA. Inhibrx | Investors - Investors
Sub-sector tags: pharma.
Capital & rounds (filed)filed
Inhibrx, Inc. has raised $669M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Growth/Late (a round over $400M).
Largest single filing: $410M on 2018-04-30.
Most recent recorded round closed around 2023-08-31.
Valuation (modeled)modeled
Provath models Inhibrx, Inc. at approximately $3.3B (range $1.2B–$4.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Too few comparable companies in this niche to rank the valuation fairly yet.
Financing rhythm & timingmixed
Historic cadence: a new round about every 16 months.
Last raise 2.8 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 13.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 100% of Biotechnology peers (4293 compared).
Modeled value ranks above 97% of those peers.
Closest niche peers: ImmunityBio, Inc., Denali Therapeutics Inc., Avidity Biosciences, Inc..
Peoplefiled
14 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.